On August 2, 2022, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) announced that it had completed its previously announced acquisition of Pharmadrug Production GmbH from Pharmadrug Inc. (CSE:PHRX) (OTC: LMLLF).

Khiron is a leading vertically integrated international medical cannabis corporation with core operations in Latin America and Europe. This acquisition will provide Khiron with a European manufacturing and distribution hub for medical cannabis and other pharmaceutical products, direct access to German pharmacies and full control of its value chain, as well as a stronger market presence with higher gross margins.
Gowling WLG advised Khiron with respect to this acquisition with a team that included Peter Simeon, Jacob Cawker and Ashley Andaya (corporate/M&A) and Paul Carenza (tax).

Read the original article on GowlingWLG.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr Peter Simeon
Gowling WLG
Suite 1600, 1 First Canadian Place
100 King Street West
M5X 1G5
Tel: 4168627525
Fax: 4168627661
E-mail: info@gowlingwlg.com
URL: www.gowlingwlg.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing